The US Food and Drug Administration (FDA) has approved the first and only triple therapy for patients 12 years and older with asthma.  AstraZeneca’s fixed-dose triple-combination therapy Breztri Aerosphere has been approved in the US for the maintenance treatment of asthma in adult and paediatric patients 12 years of age and older.   Breztri is a single-inhaler that combines the […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!